241 related articles for article (PubMed ID: 23278403)
1. Identification of novel androgen receptor antagonists using structure- and ligand-based methods.
Li H; Ren X; Leblanc E; Frewin K; Rennie PS; Cherkasov A
J Chem Inf Model; 2013 Jan; 53(1):123-30. PubMed ID: 23278403
[TBL] [Abstract][Full Text] [Related]
2. Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.
Liu B; Geng G; Lin R; Ren C; Wu JH
Chem Biol Drug Des; 2012 Mar; 79(3):300-12. PubMed ID: 22151347
[TBL] [Abstract][Full Text] [Related]
3. Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.
Gianti E; Zauhar RJ
J Chem Inf Model; 2012 Oct; 52(10):2670-83. PubMed ID: 22924551
[TBL] [Abstract][Full Text] [Related]
4. Steroid derivatives as pure antagonists of the androgen receptor.
Gauthier S; Martel C; Labrie F
J Steroid Biochem Mol Biol; 2012 Oct; 132(1-2):93-104. PubMed ID: 22449547
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays.
Pang JP; Shen C; Zhou WF; Wang YX; Shan LH; Chai X; Shao Y; Hu XP; Zhu F; Zhu DY; Xiao L; Xu L; Xu XH; Li D; Hou TJ
Acta Pharmacol Sin; 2022 Jan; 43(1):229-239. PubMed ID: 33767381
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel androgen receptor antagonists: a hybrid approach of pharmacophore-based and docking-based virtual screening.
Liu J; Liu B; Guo G; Jing Y; Zhao G
Anticancer Drugs; 2015 Aug; 26(7):747-53. PubMed ID: 25933245
[TBL] [Abstract][Full Text] [Related]
7. Endocrine Disruption at the Androgen Receptor: Employing Molecular Dynamics and Docking for Improved Virtual Screening and Toxicity Prediction.
Wahl J; Smieško M
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29914135
[TBL] [Abstract][Full Text] [Related]
8. Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.
Li H; Ban F; Dalal K; Leblanc E; Frewin K; Ma D; Adomat H; Rennie PS; Cherkasov A
J Med Chem; 2014 Aug; 57(15):6458-67. PubMed ID: 25062331
[TBL] [Abstract][Full Text] [Related]
9. Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway.
Divakar S; Saravanan K; Karthikeyan P; Elancheran R; Kabilan S; Balasubramanian KK; Devi R; Kotoky J; Ramanathan M
Chem Biol Interact; 2017 Sep; 275():22-34. PubMed ID: 28757136
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Novel Androgen Receptor Ligands by Structure-based Virtual Screening and Bioassays.
Zhou W; Duan M; Fu W; Pang J; Tang Q; Sun H; Xu L; Chang S; Li D; Hou T
Genomics Proteomics Bioinformatics; 2018 Dec; 16(6):416-427. PubMed ID: 30639122
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of MEL-3, a novel AR antagonist that suppresses prostate cancer cell growth.
Helsen C; Marchand A; Chaltin P; Munck S; Voet A; Verstuyf A; Claessens F
Mol Cancer Ther; 2012 Jun; 11(6):1257-68. PubMed ID: 22496481
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor antagonists for prostate cancer therapy.
Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
[TBL] [Abstract][Full Text] [Related]
13. A multi-parameter imaging assay identifies different stages of ligand-induced androgen receptor activation.
van Royen ME; van de Wijngaart DJ; Cunha SM; Trapman J; Houtsmuller AB
Cytometry A; 2013 Sep; 83(9):806-17. PubMed ID: 23585273
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel 5-oxo-2-thioxoimidazolidine derivatives as potent androgen receptor antagonists.
Ivachtchenko AV; Ivanenkov YA; Mitkin OD; Vorobiev AA; Kuznetsova IV; Shevkun NA; Koryakova AG; Karapetian RN; Trifelenkov AS; Kravchenko DV; Veselov MS; Chufarova NV
Eur J Med Chem; 2015 Jun; 99():51-66. PubMed ID: 26046313
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor as a therapeutic target.
Gao W
Adv Drug Deliv Rev; 2010 Oct; 62(13):1277-84. PubMed ID: 20708648
[TBL] [Abstract][Full Text] [Related]
16. Combined Ligand/Structure-Based Virtual Screening and Molecular Dynamics Simulations of Steroidal Androgen Receptor Antagonists.
Wang Y; Han R; Zhang H; Liu H; Li J; Liu H; Gramatica P
Biomed Res Int; 2017; 2017():3572394. PubMed ID: 28293633
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
18. A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides.
Guerrini A; Tesei A; Ferroni C; Paganelli G; Zamagni A; Carloni S; Di Donato M; Castoria G; Leonetti C; Porru M; De Cesare M; Zaffaroni N; Beretta GL; Del Rio A; Varchi G
J Med Chem; 2014 Sep; 57(17):7263-79. PubMed ID: 25121586
[TBL] [Abstract][Full Text] [Related]
19. The discovery of novel human androgen receptor antagonist chemotypes using a combined pharmacophore screening procedure.
Voet A; Helsen C; Zhang KY; Claessens F
ChemMedChem; 2013 Apr; 8(4):644-51. PubMed ID: 23436650
[TBL] [Abstract][Full Text] [Related]
20. Halogen-substituted anthranilic acid derivatives provide a novel chemical platform for androgen receptor antagonists.
Roell D; Rösler TW; Hessenkemper W; Kraft F; Hauschild M; Bartsch S; Abraham TE; Houtsmuller AB; Matusch R; van Royen ME; Baniahmad A
J Steroid Biochem Mol Biol; 2019 Apr; 188():59-70. PubMed ID: 30615932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
